BUSINESS

• Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
  June 19, 2026

• Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
  June 19, 2026

• Create BioVentures Sets Sail as Drug Discovery Bridge Builder
  June 19, 2026

• Merck Japan Expands Fertility Benefits, Raises Lifetime Cap to 18 Million Yen
  June 19, 2026

• Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
  June 19, 2026

• Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
  June 18, 2026

• Acumen Exercises Option for Up to Two JCR-Enabled AD Candidates
  June 18, 2026

• Takeda CEO Pulls in 2.3 Billion Yen in FY2025
  June 18, 2026

• Elevidys Needs More Safety Data to Support Full Approval: Expert
  June 18, 2026

• Sawai’s Revlimid Generic Gains Additional Lymphoma Indications
  June 18, 2026

• Efient AGs Widen Labels to Close Indication Gap
  June 18, 2026

• AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
  June 18, 2026

• Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
  June 17, 2026

• Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
  June 17, 2026

• Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
  June 17, 2026

• Torii Starts PIII Trial of Cantharidin for Common Warts
  June 17, 2026

• Ono CEO’s Pay Climbs to 260 Million Yen
  June 16, 2026

• Six Eisai Executives Took Home Over 100 Million Yen in FY2025
  June 16, 2026

• Hisamitsu to Raise Prices on Salonpas, Other OTC Products
  June 16, 2026

• Eisai to Invest £48 Million to Build Cold-Chain Capability in UK
  June 16, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »